The results reported here representa step forward in the development of novel thiazoloindazole-basedcompounds that have the potential to serve as effective AChE inhibitors.Molecular docking studies revealed that certain of the evaluated nitroindazole-basedcompounds outperformed donepezil, a well-known AChE inhibitor usedin Alzheimer’s disease treatment. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.